Evidence map›Paper›PMID 21656078›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2012

The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.

Seok-Woo Park, Dae-Seog Heo, Myung-Whun Sung

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Seok-Woo ParkCancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Dae-Seog Heo
Myung-Whun Sung
New Generation University College · ETSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt has recently been found that 5-lipoxygenase (5-LO) and cytochrome P450-2J2 (CYP2J2), molecules capable of arachidonic acid (AA) metabolism, might promote cancer cell viability through several mechanisms similar to those of cyclooxygenase-2 (COX-2). We found that not only COX-2 expression, but also the expression of 5-LO and CYP2J2 is up-regulated in head and neck squamous cell carcinoma (HNSCC) cell lines. From these observations, we hypothesized that AA metabolism by 5-LO and/or CYP2J2 may lower the efficacy of anti-cancer effect by COX-2 inhibition. METHODS AND

resultsAlthough COX-2 was highly expressed in all cell lines tested, COX-2-specific inhibition showed little growth-inhibitory effect in some cell lines. Inhibition of COX-2 resulted in increased production of LTB(4) and 14-15-DHET/EET, metabolites of 5-LO and CYP2J2, respectively. Combined knock-down of COX-2 and 5-LO or CYP2J2 by siRNA results in a decrease in cell proliferation and VEGF production. Furthermore, these results are dependent on 5-LO and CYP2J2 expression in cells.

conclusionTherefore, combined inhibition of COX-2 and 5-LO or CYP2J2 may be one way to overcome low efficacy of single inhibition of COX-2 in cancer cells. In addition, combined therapies should be chosen based on the expression of members of other AA metabolism pathways.

Indexed as

8,11,14-Eicosatrienoic AcidAntineoplastic AgentsArachidonate 5-LipoxygenaseArachidonic AcidCell Line, TumorCyclooxygenase 2Cyclooxygenase 2 InhibitorsCytochrome P-450 CYP2J2Cytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemDinoprostoneGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansLeukotriene B414,15-dihydroxyeicosatrienoic acid8,11,14-Eicosatrienoic AcidAntineoplastic AgentsArachidonate 5-LipoxygenaseArachidonic AcidCyclooxygenase 2Cyclooxygenase 2 InhibitorsCYP2J2 protein, humanCytochrome P-450 CYP2J2Cytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemDinoprostoneLeukotriene B4PTGS2 protein, humanRNA, Small InterferingVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID21656078
PMCPMC12995061
OpenAlexW2013751342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.